Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements of Armata Pharmaceuticals, Inc.:
(1) | Registration Statements (Form S-1 Nos. 333-213421, 333-217169, 333-217680, and 333-226959), |
(2) | Registration Statements (Form S-3 Nos. 333-237533, 333-237534, and 333-256104), |
(3) | Registration Statement (Form S-8 No. 333-203455) pertaining to the 2012 Stock Incentive Plan and 2013 Stock Incentive Plan, |
(4) | Registration Statements (Form S-8 Nos. 333-212183, 333-217563 and 333-223987) pertaining to the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan and Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, |
(5) | Registration Statements (Form S-8 Nos. 333-221564 and 333-232058) pertaining to the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, as amended, C3J Jian, Inc. Amended 2006 Stock Option Plan and C3J Therapeutics, Inc. 2016 Stock Plan, and |
(6) | Registration Statement (Form S-8 No. 333-250034) pertaining to the Inducement Restricted Stock Unit Award (October 2020); |
of our report dated March 17, 2022, with respect to the consolidated financial statements of Armata Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Armata Pharmaceuticals, Inc. for the year ended December 31, 2021.
/s/ Ernst & Young LLP
San Diego, California
March 17, 2022